Wilms Cancer Foundation
Defeating Childhood Kidney Cancer
TM
.png)
Wilms Tumor (Nephroblastoma) in Children: Symptoms, Diagnosis, Treatment, Survival, Relapse, Long-term Effects & Childhood Kidney Cancer Support
The international Wilms tumor charity website of the Wilms Cancer Foundation providing the world's most comprehensive free resource dedicated to Wilms tumor (nephroblastoma) and childhood kidney cancer, featuring evidence-based information on symptoms, diagnosis, staging, treatment, surgery, chemotherapy, radiation therapy, relapse, survivorship, long-term effects, clinical trials, patient support, nutrition, and family resources for children, parents, caregivers, survivors, healthcare professionals, and childhood cancer communities worldwide.
Wilms tumor Research Papers & PubMed Studies
What's on this page:
Explore Wilms tumor research papers, PubMed studies, peer-reviewed scientific literature, and childhood kidney cancer publications from researchers and pediatric oncology groups around the world. Discover studies covering Wilms tumor biology and genetics, molecular biomarkers, diagnosis and pathology, treatment, surgery, chemotherapy, clinical trials, relapsed and high-risk disease, survival, survivorship, late effects, and long-term outcomes, with direct links to PubMed, scientific journals, and original published research for further reading.
Explore Wilms Tumor Research Papers, PubMed Studies & Scientific Literature
Welcome to the Wilms Cancer Foundation Papers & PubMed page, a dedicated resource for exploring Wilms tumor research papers, PubMed studies, peer-reviewed scientific literature, and published childhood kidney cancer research from around the world. This research library brings together important scientific publications covering the breadth of Wilms tumor and pediatric renal tumor research, including tumor biology, genetics, molecular biomarkers, pathology, diagnosis, staging, surgery, chemotherapy, radiotherapy, clinical trials, relapse, high-risk disease, survival, surveillance, late effects, and long-term survivorship.
As a global organization dedicated specifically to Wilms tumor and childhood kidney cancer, the Wilms Cancer Foundation works to improve access to trusted scientific knowledge and help connect families, healthcare professionals, researchers, advocates, and the wider childhood cancer community with research relevant to understanding and treating Wilms tumor. Through the Global Wilms Tumor Initiative™ (GWTI), the Wilms Tumor Knowledge Index™ (WTKI), and engagement with researchers, healthcare institutions, international organizations, and childhood cancer partners, the Foundation supports the exchange and accessibility of knowledge that can contribute to continued progress in Wilms tumor research and care.
This page provides access to peer-reviewed Wilms tumor research papers and scientific studies, with concise WCF summaries explaining the focus and potential relevance of each publication alongside links to PubMed, scientific journals, and original published research. Explore studies from international pediatric oncology researchers and collaborative groups investigating areas such as Wilms tumor genetics and genomics, tumor development, molecular risk factors, treatment response, chemotherapy resistance, surgical techniques, relapsed and refractory disease, precision medicine, survivorship, and global treatment outcomes.
The Papers & PubMed collection is designed to complement WCF's Research News service. Research News provides accessible coverage and explanation of significant developments, while Papers & PubMed provides a deeper gateway into the underlying scientific literature and primary research. Together, these resources allow readers to follow both the evolving research landscape and the published evidence behind advances in our understanding of Wilms tumor.
Scientific research continually changes our understanding of childhood kidney cancer, but findings reported in an individual paper do not necessarily represent established clinical practice or a treatment recommendation. WCF provides these publications for education, research awareness, and knowledge sharing. Families and caregivers should discuss research that may be relevant to an individual child's diagnosis or treatment with their pediatric oncology team.
Wilms Tumor: Diagnosis and Updates
September 2, 2026
Diagnostic Pathology — Lauren N. Parsons & Amy L. Treece.
A very recent open-access review covering contemporary Wilms tumor diagnosis, pathology and molecular developments, including segmental chromosomal alterations.
Read the full article
PRAME-Specific T-Cell Therapy in Advanced Pediatric Nephroblastoma
August 2026
New England Journal of Medicine. Particularly newsworthy: this reports PRAME-targeted T-cell therapy in a child with advanced nephroblastoma. The authors reported a 69% tumor reduction, with molecular, metabolic and histologic evidence of complete remission at 200 days. This is a single-patient report, so it should be presented as promising early evidence rather than an established treatment.
Read in the New England Journal of Medicine
Single-Nucleus RNA Sequencing Reveals Transcriptional Heterogeneity in the Blastema of Favorable-Histology Wilms Tumor
August 2026
JCI Insight. This research uses single-nucleus RNA sequencing to investigate heterogeneity within the blastemal component of favorable-histology Wilms tumors—highly relevant to the tumor biology/genomics section of Research News.
View the PubMed article and full-text links
Tumor Volume Reduction After Neoadjuvant Chemotherapy in Childhood Nephroblastoma: Radiological, Histopathological, and Clinical Correlates in Tanzania
June 2026
Pediatric Hematology Oncology Journal. This is particularly valuable for WCF's global Wilms tumor coverage. The study examines CT-measured tumor-volume reduction following preoperative chemotherapy and its relationship with histopathology and clinical factors in Tanzania.
Read the open-access article
Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors
May 18, 2026
JCO Precision Oncology. A substantial review of molecular biomarkers relevant to Wilms tumor risk stratification, including 1q gain, 1p/16q alterations, TP53, MYCN, WT1, SIX1/SIX2, DROSHA, DGCR8, CTNNB1 and other molecular alterations.
Read the JCO Precision Oncology article
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study
2026
Journal of Clinical Oncology. This is an important SIOP study examining whether the absolute volume of residual blastema after preoperative chemotherapy provides prognostic information in Wilms tumor.
Read the Journal of Clinical Oncology article
View on PubMed
Differential Immune Infiltrates in Histomorphologic Wilms Tumor Regions Identify Prognostic Macrophages
March 19, 2026
Molecular Therapy Oncology. This open-access original study investigated immune-cell infiltration across blastemal, epithelial and mesenchymal regions of Wilms tumors and evaluated associations with prognosis.
Read the open-access article
Long-Term Adverse Effects of Modern Wilms Tumour Therapies: Implications for Monitoring
January 26, 2026
Nature Reviews Urology. A particularly useful paper for the survivorship and late-effects branch of the WCF site. It examines anticipated late morbidity associated with contemporary Wilms tumor treatments and proposes a patient-centered approach to follow-up.
Nature's Wilms tumour research collection and article listing
More News & Media
Stay up to date with the latest news, international partnerships, programme launches, conference participation, press releases, and global developments from the Wilms Cancer Foundation as we work with leading organizations to improve outcomes for children diagnosed with Wilms tumor worldwide.
Read more about News & Media
Press Releases
Browse the latest official announcements from the Wilms Cancer Foundation, including new partnerships, programme launches, international initiatives, research collaborations, advocacy activities, and organizational milestones.
Explore the latest news at the Wilms Cancer Foundation
WHO, GICC & CureAll Announcement
Learn how the Wilms Cancer Foundation supports and works with the World Health Organization (WHO), the Global Initiative for Childhood Cancer (GICC), and the CureAll Framework through education, advocacy, international collaboration, and healthcare capacity building.
Read more about the WHO (GICC & CureAll) Partnership Announcement with the WCF
St. Jude Collaboration Announcement
Find out how the Wilms Cancer Foundation is collaborating with St. Jude Children's Research Hospital to strengthen international education, healthcare professional engagement, and global initiatives supporting children with Wilms tumor.
Read more about the international St. Jude Collaboration with the Wilms Cancer Foundation
WHO Global Status Report on Cancer 2026 Announcement
Explore the Foundation's contribution to the WHO Global Status Report on Cancer 2026 and learn how our expertise is helping support international efforts to improve childhood cancer care worldwide.
Read more about the WHO Global Status Report on Cancer 2026
Wilms Tumor WebApp™ Launch
Discover the launch of the Wilms Tumor WebApp™, an innovative digital platform designed to provide parents, healthcare professionals, researchers, and students with free access to trusted, evidence-based information and educational resources.
Read more about the Wilms Tumor WebApp™ Launch
Wilms Tumor Ai™ Launch
Learn about the launch of Wilms Tumor Ai™, an intelligent educational support platform that helps families and healthcare professionals quickly access reliable information about Wilms tumor, treatment, survivorship, and global resources.
Read more about Wilms Tumor Ai™ and its impact on Wilms care
Conference News
Keep up to date with the Foundation's participation in international pediatric oncology conferences, scientific meetings, educational events, and presentations that help advance global collaboration and knowledge sharing.
Wilms tumor Symptoms
Wilms tumor symptoms may include abdominal swelling, stomach pain, blood in the urine, fatigue, fever, and other early warning signs of childhood kidney cancer.